Take Action

Support Medicare Diagnostic Radiopharmaceutical Payment Equity!

Nuclear medicine uses very small amounts of radioactive material in drugs (radiopharmaceuticals) to provide detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures offer pictures of physical structure, nuclear imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes. These precision nuclear imaging procedures can often identify abnormalities very early in the progress of a disease — long before many medical problems are apparent with other diagnostic tests. However, many patients are limited in their access to life-saving nuclear medicine because of the design of the current Medicare Hospital Outpatient Prospective Payment System (OPPS).

Congress can fix this issue and protect access to nuclear medicine by passing H.R. 3772, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 which would reform OPPS to adequately pay for advanced nuclear imaging services.

You can quickly and easily demonstrate your support for this legislation by writing your lawmakers with our advocacy tool. Please join us in asking them to support this important legislation.